Chemours (NYSE:CC) Shares Gap Up - Here's Why

Key Points

• Chemours shares opened sharply higher, rising from a prior close of $13.16 to $14.48, after the company issued fourth-quarter revenue guidance of $1.7 billion to $1.8 billion—well above the $1.4 billion analyst consensus.
• The company reported third-quarter revenue of $1.54 billion, up 3% year over year and slightly above estimates, but adjusted EPS of $0.21 missed expectations and fell from $0.40 a year earlier, highlighting continued profitability concerns.
• Chemours launched Faizeon liquid-cooling solutions aimed at AI and high-density data centers, while analysts remain cautious with a consensus “Hold” rating and $17.73 price target; the company also faces securities-fraud litigation allegations related to Opteon product demand.

The Chemours Company (NYSE:CC - Get Free Report)'s share price gapped up prior to trading on Tuesday. The stock had previously closed at $13.16, but opened at $14.48. Chemours shares last traded at $13.3550, with a volume of 260,401 shares changing hands.

Chemours News Roundup

Here are the key news stories impacting Chemours this week:

• Positive Sentiment: Chemours issued fourth-quarter 2026 revenue guidance of $1.7 billion to $1.8 billion, well above the $1.4 billion analyst consensus. Full-year revenue guidance of $5.9 billion was in line with expectations, providing some support for the outlook.
• Positive Sentiment: The company launched its Faizeon two-phase liquid-cooling portfolio for AI, high-performance computing, and high-density data centers. The products are designed to manage rising computing heat loads while reducing energy and water consumption, potentially expanding Chemours’ exposure to data-center growth. Chemours Launches Faizeon Two-Phase Liquid Cooling Solutions for AI Data Centers
• Positive Sentiment: At least one recent analyst article upgraded Chemours, arguing that patient investors could benefit from a potential recovery. Chemours: Patient Investors Can Be Rewarded
• Neutral Sentiment: Third-quarter revenue rose 3% year over year to $1.54 billion, slightly above the $1.53 billion consensus estimate. However, management reported adjusted EPS of $0.21 versus the $0.26 expected.
• Negative Sentiment: The earnings shortfall, declining EPS from $0.40 a year earlier, and a reported negative net margin of 5% raise concerns about profitability and operating momentum. Chemours Reports Third Quarter Results
• Negative Sentiment: Several law firms publicized a securities class action alleging that Chemours misrepresented demand for its Opteon products before a major stock decline and subsequent guidance concerns. The allegations are not proven, but the litigation creates legal, reputational, and potential financial risks for investors; the lead-plaintiff deadline is December 7, 2026. Chemours Securities Fraud Class Action Notice

Wall Street Analysts Forecast Growth

CC has been the subject of several recent research reports. Mizuho lowered Chemours from an "outperform" rating to a "neutral" rating and dropped their price target for the stock from $18.00 to $15.00 in a research report on Wednesday, October 14th. Royal Bank Of Canada downgraded Chemours from an "outperform" rating to a "sector perform" rating and set a $14.00 price objective for the company. in a report on Tuesday, October 13th. The Goldman Sachs Group restated a "neutral" rating and issued a $16.00 price target on shares of Chemours in a report on Friday, October 9th. Weiss Ratings downgraded shares of Chemours from a "sell (d)" rating to a "sell (d-)" rating in a report on Thursday, August 6th. Finally, Truist Financial lowered their price target on Chemours from $24.00 to $20.00 and set a "buy" rating for the company in a research report on Tuesday, October 20th. Three analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Chemours presently has an average rating of "Hold" and a consensus price target of $17.73.

Chemours Trading Up 2.3%

The stock has a market capitalization of $2.03 billion, a PE ratio of -7.03 and a beta of 1.41. The company has a debt-to-equity ratio of 18.98, a current ratio of 1.66 and a quick ratio of 0.88. The company's 50 day moving average price is $14.17 and its two-hundred day moving average price is $18.26.

Chemours (NYSE:CC - Get Free Report) last issued its earnings results on Monday, November 2nd. The specialty chemicals company reported $0.21 earnings per share for the quarter, missing the consensus estimate of $0.26 by ($0.05). Chemours had a positive return on equity of 60.64% and a negative net margin of 5.00%. The company had revenue of $1.54 billion for the quarter, compared to analyst estimates of $1.53 billion. During the same quarter in the prior year, the firm earned $0.40 earnings per share. The company's revenue for the quarter was up 3.0% on a year-over-year basis. As a group, analysts expect that The Chemours Company will post 0.83 earnings per share for the current year.

Chemours Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 15th. Investors of record on Monday, November 16th will be given a $0.0875 dividend. This represents a $0.35 annualized dividend and a yield of 2.6%. The ex-dividend date is Monday, November 16th. Chemours's dividend payout ratio is presently -18.32%.

Insider Buying and Selling at Chemours

In other Chemours news, insider Calderon Gerardo Familiar purchased 1,935 shares of the firm's stock in a transaction dated Wednesday, August 12th. The shares were acquired at an average price of $15.53 per share, with a total value of $30,050.55. Following the purchase, the insider directly owned 58,547 shares in the company, valued at approximately $909,234.91. This trade represents a 3.42% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CEO Denise Dignam purchased 3,378 shares of the stock in a transaction dated Tuesday, August 11th. The shares were acquired at an average price of $14.95 per share, with a total value of $50,501.10. Following the completion of the acquisition, the chief executive officer owned 339,916 shares in the company, valued at approximately $5,081,744.20. This trade represents a 1.00% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have acquired 8,663 shares of company stock worth $130,601 over the last quarter. 0.85% of the stock is currently owned by company insiders.

Institutional Trading of Chemours

Several institutional investors have recently added to or reduced their stakes in CC. Northwestern Mutual Wealth Management Co. purchased a new stake in shares of Chemours during the second quarter worth approximately $34,000. Allworth Financial LP purchased a new stake in Chemours in the second quarter valued at $51,000. State of Wyoming acquired a new position in Chemours in the second quarter valued at $67,000. Sterling Capital Management LLC boosted its stake in Chemours by 839.3% in the third quarter. Sterling Capital Management LLC now owns 5,072 shares of the specialty chemicals company's stock valued at $69,000 after acquiring an additional 4,532 shares in the last quarter. Finally, Nykredit A S purchased a new stake in shares of Chemours in the 2nd quarter valued at about $99,000. Institutional investors and hedge funds own 76.26% of the company's stock.

Chemours Company Profile

The Chemours Company NYSE: CC is a global chemistry company that develops and manufactures performance chemicals and advanced materials for industrial and consumer applications. The company serves customers in markets including automotive, construction, energy, electronics, healthcare, and general manufacturing.

Chemours operates through businesses focused on Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. Its products include titanium dioxide pigments used to provide whiteness and opacity in coatings, plastics, and paper; refrigerants and related thermal-management solutions; and high-performance fluoropolymers and specialty materials sold under brands such as Teflon™, Viton™, and Nafion™.

Headquartered in Wilmington, Delaware, Chemours serves customers globally through manufacturing facilities, research and development operations, and commercial activities across North America, Latin America, Europe, and Asia-Pacific.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.